Evidence map›Paper›PMID 38731874›Full record

ArticleInternational journal of molecular sciences2024

Peptides Targeting the IF1-ATP Synthase Complex Modulate the Permeability Transition Pore in Cancer HeLa Cells.

Martina Grandi, Simone Fabbian, Giancarlo Solaini, Alessandra Baracca, Massimo Bellanda, Valentina Giorgio

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Martina GrandiDepartment of Biomedical and Neuromotor Sciences, University of Bologna, 40126 Bologna, Italy.ORCID 0000-0002-5203-3416
Simone FabbianDepartment of Chemical Science, University of Padova, 35121 Padova, Italy.ORCID 0000-0002-1409-2757
Giancarlo SolainiDepartment of Biomedical and Neuromotor Sciences, University of Bologna, 40126 Bologna, Italy.ORCID 0000-0001-7825-0446
Alessandra BaraccaDepartment of Biomedical and Neuromotor Sciences, University of Bologna, 40126 Bologna, Italy.ORCID 0000-0002-0490-1776
Massimo BellandaDepartment of Chemical Science, University of Padova, 35121 Padova, Italy.
Valentina GiorgioDepartment of Biomedical and Neuromotor Sciences, University of Bologna, 40126 Bologna, Italy.ORCID 0000-0002-4229-3054

Funding

Italian Association for Cancer Research MFAG 2017 - ID. 20316Ministry of Education, Universities and Research PRIN 2017 - ID. 201789LFKB
6 · The paper itself

Abstract

The mitochondrial protein IF1 is upregulated in many tumors and acts as a pro-oncogenic protein through its interaction with the ATP synthase and the inhibition of apoptosis. We have recently characterized the molecular nature of the IF1-Oligomycin Sensitivity Conferring Protein (OSCP) subunit interaction; however, it remains to be determined whether this interaction could be targeted for novel anti-cancer therapeutic intervention. We generated mitochondria-targeting peptides to displace IF1 from the OSCP interaction. The use of one selective peptide led to displacement of the inhibitor IF1 from ATP synthase, as shown by immunoprecipitation. NMR spectroscopy analysis, aimed at clarifying whether these peptides were able to directly bind to the OSCP protein, identified a second peptide which showed affinity for the N-terminal region of this subunit overlapping the IF1 binding region. In situ treatment with the membrane-permeable derivatives of these peptides in HeLa cells, that are silenced for the IF1 inhibitor protein, showed significant inhibition in mitochondrial permeability transition and no effects on mitochondrial respiration. These peptides mimic the effects of the IF1 inhibitor protein in cancer HeLa cells and confirm that the IF1-OSCP interaction inhibits apoptosis. A third peptide was identified which counteracts the anti-apoptotic role of IF1, showing that OSCP is a promising target for anti-cancer therapies.

Indexed as

MitochondriaMitochondrial Proton-Translocating ATPasesPeptidesApoptosisATPase Inhibitory ProteinHeLa CellsHumansMitochondrial Membrane Transport ProteinsMitochondrial Permeability Transition PoreProtein BindingATPase Inhibitory ProteinMitochondrial Membrane Transport ProteinsMitochondrial Permeability Transition PoreMitochondrial Proton-Translocating ATPasesPeptidesATP synthasecancerinhibitor protein IF1mitochondriapermeability transition poretherapy

Identifiers

PMID38731874
PMCPMC11083241

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.